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Assessment of intratumor 
immune-microenvironment in colorectal 
cancers with extranodal extension of nodal 
metastases
Matteo Fassan1*† , Luca Vianello1†, Diana Sacchi1†, Giuseppe N. Fanelli1, Giada Munari1, Marco Scarpa2, 
Rocco Cappellesso1, Fotios Loupakis3, Cristiano Lanza1, Roberta Salmaso1, Claudia Mescoli1, Nicola Valeri4,5, 
Marco Agostini2,6,7, Edoardo D’Angelo2, Sara Lonardi3, Salvatore Pucciarelli4, Nicola Veronese8,11, 
Claudio Luchini9 and Massimo Rugge1,10
Abstract 
Background: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node 
metastasis (LN) in colorectal cancer (CRC).
Methods: A series of 22 ENE-positive CRCs was considered and three samples per case were selected (the primary 
CRC, an ENE-negative and an ENE-positive metastatic LN). Samples (n = 66) were analysed by immunohistochemistry 
for PD-L1, CD4, CD8, CD68 and CD80. Fifteen out of twenty-two cases were further profiled through a hotspot mul-
tigene mutational custom panel, including 164 hotspot regions of AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, 
PIK3CA, PTEN and TP53 genes.
Results: A significantly higher percentage of CD4-, CD8- and CD68-positive cells was observed at the invasive front 
of both CRCs and in ENE in contrast with what observed at the core of both CRCs and their matched nodal metas-
tases. ENE was also characterized by a significantly higher number of CD80-positive cells. No significant difference 
was observed in PD-L1 distribution among the different specimens. Fourteen out of 15 CRCs (93%) showed at least 
a driver mutation. The most frequently mutated gene was TP53 (n = 8 tumors), followed by APC (n = 6), BRAF (n = 4), 
KRAS, NRAS and PIK3CA (n = 2). In 11 out of 15 CRCs (73%) the mutational profiling of the primary tumor was consist-
ent with what obtained from the two matched LNs.
Conclusions: A heterogeneous intratumor immune-microenvironment has been observed in ENE-positive CRCs, 
which are characterized by an increased leukocytic infiltration at the ENE invasive front.
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Background
Colorectal cancer (CRC) is the third more frequent can-
cer and the fourth cause of cancer death all over the 
world [1].
CRC survival is mainly dependent upon the tumor-
node-metastasis (TNM) stage of disease at diagnosis 
[1, 2]. However, not all the patients, who have the same 
stage, show comparable prognoses. Therefore, further 
research is needed to identify novel prognostic factors for 
the stratification of risk of recurrence in patients classi-
fied with the same stage of disease.
Recently, the extra-nodal extension (ENE) of nodal 
metastasis has emerged as a promising and independ-
ent prognostic factor in several epithelial malignancies 
[3–14].
From the pathological point of view, ENE is different 
from free tumor deposits in the fibroadipose tissue, even 
if both conditions present similar phenotypic features. 
In contrast to what is observed in ENE, tumor depos-
its do not present residual nodal tissue and are consid-
ered as a separate entity in the tumor-node-metastasis 
(TMN) staging system, having a specific category into the 
N group (i.e. N1c) [15]. On the other hand, ENE, which 
is defined by an invasion of cancer cells/glands from an 
intra-nodal metastasis through the lymph node capsule, 
is still not considered in the TNM system as a prognostic 
parameter in nodal-metastatic CRC patients.
In a recent meta-analysis from our group, specifically 
designed on the prognostic role of ENE in CRC [16], 
we demonstrated the importance of such parameter in 
influencing the survival of CRC patients. Notably, 611 
patients out of the analysed nodal-positive 1336 (45.7%), 
showed an ENE-positive status, Indicating that ENE is a 
frequent condition among CRC metastatic tumors.
The invading potential of tumor cells through the LN 
capsule may reflect the aggressiveness acquired from 
a clone deriving from the primary tumor or occurring 
within the metastatic nodes [17]. Therefore, several 
authors have proposed the detection and quantification 
of ENE in the surgical specimen as a novel diagnostic 
tool for a correct assessment of tumor staging and for a 
personalization of adjuvant therapy [16]. However, no 
information is available on the molecular mechanisms 
underpinning the ENE phenotype. Thus, the main aim 
of this work was the investigation of the heterogeneous 
intratumor molecular landscape and immune-microenvi-
ronment in a series of ENE-positive CRCs.
Materials and methods
Patients and samples
A series of consecutive 65 TNM stages III (n = 45) and 
IV (n = 20) formalin-fixed paraffin embedded (FFPE) 
primary CRC and their matched LNs were retrieved 
from the archives of the Surgical Pathology Unit of the 
Padua University (samples collected in year 2016). The 
study was approved by the local Ethic Committee (n. 
0032705/16).
Patients who had received neoadjuvant chemo-radi-
otherapy, patients under the age of 20, and cases with a 
number of histologically examined LNs lower than 12 
were excluded from the selection.
Two gastrointestinal pathologists, who were unaware 
of any clinical information, re-evaluated all the original 
haematoxylin and eosin stained slides according to the 
2010 World Health Organization classification [18]. The 
presence of ENE was defined as an extension of tumor 
cells through the nodal capsule into the perinodal adi-
pose tissue [5] and it was assessed as present or absent. 
Tumor cell nodules in perivisceral adipose tissue, which 
are not connected with the primary tumor and are not 
surrounded by lymphoid tissue, were excluded due to a 
consideration of them as tumor deposits.
Only cases with adequate material for the subsequent 
molecular characterization were selected. In each case 
three different matched samples were obtained: (i) the 
primary CRC; (ii) a metastatic LN with no extranodal 
extension of the tumor (i.e. ENE-negative LNs were 
entirely examined by serial sections to exclude the pre-
sent of extra-nodal involvement); (iii) an ENE positive 
metastatic LN.
A total of 26 cases resulted ENE positive, but ade-
quate material was available only for 22 (M/F = 15/7; age 
70.2 ± 13.7, range 40–89; grading G2 = 4, G3 = 18; stag-
ing IIIb = 2, IIIc = 14, IV = 6; all Caucasian; DNA mis-
match repair machinery deficient tumors [MMRd] = 4, 
all with defects in MLH1/PMS2 expression). Thus, a total 
of 66 samples (i.e. three per case) were selected and fur-
ther analysed.
Immunohistochemistry
Immunohistochemical stains for PD-L1 (clone 22C3; 
Dako, Glostrup, Denmark), CD4 (Dako), CD8 (Dako), 
CD68 (Dako), CD80 (Novus Biologicals, Littleton, CO), 
MLH1 (ES05; Dako), MSH2 (clone FE11; Dako), MSH6 
(clone EP49; Dako), and PMS2 (clone EP51; Dako) were 
automatically performed in 3–4  μm sections using the 
Bond Polymer Refine Detection kit (Leica Biosystems, 
Newcastle upon Tyne, UK) in the BOND-MAX system 
(Leica Biosystems). Appropriate positive and negative 
controls were run concurrently.
PD-L1 expression was assessed both in neoplastic 
epithelia and in infiltrating lymphocytes. The positive 
neoplastic cells percentage was evaluated jointly by two 
pathologists. For epithelial immunoreactivity, only mod-
erate/strong membranous staining up to 1% was con-
sidered positive. Stromal positive lymphoid cells were 
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evaluated in five HPF (40×) in different areas of the 
samples: (i) central part of the primary CRC; (ii) invasive 
front of the primary CRC; (iii) intratumoral infiltration of 
the metastatic LN sample; (iv) intratumoral infiltration of 
the ENE positive LN sample; (v) invasive front of the ENE 
positive LN sample (Fig. 1). Presence of lymph node-like 
structures at the edge of the primary tumors were not 
considered in the analysis. Stromal PD-L1 positive cells 
infiltration of tumors was assessed by semiquantitative 
estimation of the density of PD-L1-positive cells, and was 
scored as 0, no positive cell; (1) sporadic PD-L1+ cells; (2) 
moderate numbers of PD-L1+ cells; (3) abundant occur-
rence of PD-L1+ cells.
The infiltrating CD4, CD8, CD68 and CD80 leukocytes 
were counted in five HPF of the previously mentioned 
five randomly selected tumor areas and final counts were 
normalized within the same case.
DNA mismatch repair machinery deficient tumors 
(MMRd) were defined by the absence of nuclear stain-
ing in one of the two heterodimers MLH1/PMS2 and/or 
MSH2/MSH6 in tumor cells, as assessed in the colorectal 
setting [19].
Hotspot multigene mutational profiling
DNA was obtained from the FFPE samples after enrich-
ment for neoplastic cells, as previously described with 
minor modifications [20]. Suitable areas for microdissec-
tion were selected from the archival haematoxylin and 
eosin slides and the corresponding tissue blocks were 
serially cut to 10-μm-thin sections. Unstained sections 
were, subsequently, deparaffinized and slightly counter-
stained with haematoxylin. Tumor cells were dissected 
manually using a sterile syringe needle, and at least 60% 
of neoplastic cells were collected from the primary car-
cinoma and two different metastatic lymph-node, one of 
which characterized by the presence of ENE. In the ENE-
positive lymph-node, only the region with extracapsular 
extension was considered for microdissection. DNA was 
extracted using the QIAamp DNA formalin-fixed, paraf-
fin-embedded tissue kit (Qiagen, Milan, Italy) and quali-
fied as previously performed [21].
DNA obtained from the microdissected tumor com-
ponents underwent hotspot multigene mutational pro-
filing including 164 hotspot regions of the AKT1, APC, 
BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, 
PTEN and TP53 genes using a custom panel (Diatech 
Pharmacogenetics, Jesi, Italy; primers and protocol avail-
able upon request) run on a MassARRAY Dx Analyzer 
4 (Agena Bioscience, Hamburg, Germany) [22]. The 
observed somatic mutations were confirmed by Sanger 
sequencing (Applied Biosystems 3130xl Genetic Ana-
lyser; Life Technologies, Monza, Italy).
Statistical analysis
The strength of the association between the different his-
tological lesions and the immunohistochemical/molecu-
lar features was calculated by applying the Wilcoxon 
signed-rank test and the Mann–Whitney test, as appro-
priate. Stata software (Stata Corporation, College Station, 
TX) was used for all calculations. A p value < 0.05 was 
considered significant.
Results
ENE phenotype is characterized by an enhanced 
inflammatory response at the invasive front
A series of 22 ENE-positive CRCs were analysed by 
immunohistochemistry for PD-L1, CD4, CD8, CD68 
and CD80 expression. For each case, three different sam-
ples were considered and analysed: the primary CRC, an 
ENE-negative and an ENE-positive metastatic LN.
Immunohistochemical analyses showed a significantly 
higher percentage of CD4-, CD8- and CD68-positive 
cells at the CRC and ENE invasive fronts in comparison 
with what observed at the core of both CRCs and their 
matched ENE-negative nodal metastases (Fig. 1a).
For CD4, the normalized number of positive T-cells 
was 1.82-fold higher in the CRC invasive front in com-
parison of the number of positive cells observed at the 
center of the tumor (p = 0.0026; paired t test) and 1.71 in 
ENE invasive front in comparison to the matched ENE-
negative metastatic LNs (p = 0.029; paired t-test).
For CD8, the normalized number of positive T-cells 
was 3.04-fold higher in the CRC invasive front in com-
parison of the number of positive cells observed at the 
center of the tumor (p < 0.0001; paired t-test) and 1.74 in 
ENE invasive front in comparison to the matched ENE-
negative metastatic LNs (p = 0.008; paired t-test).
(See figure on next page.)
Fig. 1 a Immunohistochemical characterization of 22 ENE-positive colorectal carcinomas. In each case, stromal positive lymphoid T cells were 
evaluated in five high-power fields (40×) in different areas of the samples: (i) central part of the primary CRC; (ii) invasive front of the primary CRC; 
(iii) intratumoral infiltration of the metastatic LN sample; (iv) intratumoral infiltration of the ENE positive LN sample; (v) invasive front of the ENE 
positive LN sample. A significantly higher percentage of CD4-, CD8- and CD68-positive cells was observed at the invasive front of both CRCs and 
in ENE in contrast with what observed at the core of both CRCs and their matched nodal metastases. ENE was also characterized by a significantly 
higher number of CD80-positive cells. (*p < 0.05; **p < 0.01; ***p < 0.001). b Representative images of CD80-positive cells distribution within the 
considered samples (original magnifications 20× and 40×; scale bars = 100 µm)
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For CD68, the normalized number of positive mac-
rophages was 2.08-fold higher in the CRC invasive front 
in comparison of the number of positive cells observed 
at the center of the tumor (p < 0.0001; paired t-test) and 
1.45 in ENE invasive front in comparison to the matched 
ENE-negative LNs (p = 0.015; paired t-test).
A significantly higher prevalence of CD80-positive cells 
was detected in the ENE samples only (Fig. 1a, b). In par-
ticular, the normalized number of positive cells was 2.70-
fold higher in ENE invasive front in comparison to the 
matched ENE-negative LNs (p < 0.001; paired t-test).
No significant number of epithelial, or leukocytic 
PD-L1 positive cells was observed among the different 
considered samples.
The four cases with MMRd presented a relatively, but 
not significant, higher number of CD4 and CD8 infiltrat-
ing cells (in both primary and metastatic LNs) in com-
parison to MMR proficient (MMRp) cases, and were also 
characterised by a higher number of CD4/CD8 positive 
cells at both the CRC invasive front in comparison to the 
center of the tumor and in ENE invasive front in compar-
ison to the matched ENE-negative metastatic LNs.
No specific mutational signature characterizes the ENE 
phenotype
Fifteen out of the original series of 22 cases were further 
profiled through a hotspot multigene mutational custom 
panel.
In primary tumors, a total of 25 somatic mutations 
were observed among the 11 cancer-related genes 
(Fig. 2). In 14 of 15 (93%) primary CRC samples, at least 
one somatic mutation was detected; eight lesions were 
found to have multiple driver gene somatic mutations.
The TP53 gene was the most frequently mutated gene 
(8 out of 15), followed by APC (six cases) and BRAF 
(four cases; all MMRd). KRAS, NRAS and PIK3CA were 
mutated in two cases at most. In 11 out of 15 (73%), the 
molecular profiling of the primary CRC was consistent 
with that of its matched metastatic LNs, whereas a dis-
crepancy between the mutational profiling of the primary 
CRC and its matched metastatic LNs was found in four 
cases (Fig. 2).
The detected allele frequencies of the mutations 
observed in the four discordant cases was consistent 
with either polyclonal expansion or monoclonal prolif-
eration of the disease (intra-tumor heterogeneity) in line 
with recent evidence suggesting that nodal dissemination 
from primary CRCs is not necessarily related to genetic 
bottlenecks [23].
No significant association was observed between a 
peculiar mutational profile and an increase/decrease in 
inflammatory infiltration.
Discussion
For many years, the interest in oncological research has 
focused on understanding the mechanisms that would 
induce the acquisition of an aggressive phenotype by the 
neoplastic cells. This may represent the biological ration-
ale in the development of new therapeutics which, on 
one side, would impair the metastatic ability and, on the 
other, personalize the oncological and surgical manage-
ments of the disease.
Worldwide, CRC is a major cause of morbidity and 
mortality [1, 2]. The TNM staging system represents the 
best patient’s prognostic factor at time of the diagnosis. 
Although the TNM staging system is constantly updated, 
outcomes of patients with similar histological features 
falling within the same risk category may have heteroge-
neous outcomes (i.e. pT3pN1 versus pT4 and/or pN2 in 
Stage III CRC) thus impacting on clinical decisions [24]. 
It is, therefore, clear that there is an unmet need to iden-
tify new prognostic factors to better stratify the patients, 
both from a histological and molecular point of view.
The detection of ENE has been demonstrated to be an 
important prognostic factor in many epithelial cancers 
[3–14]. Indeed, the latest TNM edition has highlighted 
the need to report the presence of ENE in lymph node 
metastasis in case of the head and neck tumors and the 
vulvar squamous cell carcinoma [25, 26].
Several lines of evidence have proven that, even in 
CRC, the presence of ENE correlates with a patient’s poor 
prognosis both in terms of risk of recurrence and overall 
survival [4, 7, 27–30].
Despite the recognized prognostic impact of the ENE 
phenotype, no previous work has tried to elucidate its 
molecular landscape. One of the bottlenecks in this field 
is the (almost) mandatory use of formalin-fixed paraffin-
embedded (FFPE) specimens, which potentially affects 
many down-stream molecular pathology analyses [31]. 
Moreover, most of the lesions are small and, thus, their 
comprehensive molecular characterization is technically 
challenging.
Starting from archival FFPE material, we investigated: 
(i) the ENE-associated inflammatory infiltrate by immu-
nohistochemistry; (ii) the ENE molecular background by 
applying a FFPE-friendly custom panel to characterize 
164 hotspot regions of CCR-related genes. Of the initial 
series of 65 consecutive TNM stages III and IV primary 
CRC and their matched metastatic LNs, only 22 pre-
sented adequate material for the subsequent molecular 
characterization.
The immunohistochemical evaluation for the presence 
of tumor-infiltrating T lymphocytes (CD4 and CD8) and 
macrophages (CD68) demonstrated a significantly higher 
prevalence of inflammatory infiltrate at the neoplastic 
invasive front of the primary tumor and of the ENE in 
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contrast with what observed at the core of both CRCs 
and their matched intra-nodal metastases. These data 
suggest that there is a common host-related inflamma-
tory systemic response against the infiltrating neoplastic 
cells. An important negative aspect of this study is the 
lack of a comprehensive tumor immune microenviron-
ment characterization, which was not possible due to the 
limited amount of (FFPE) material. Further expression 
profiling studies should investigate the role of the differ-
ent tumor areas/tumor-associated stroma in the polari-
zation of the monocyte-macrophage lineage and of the 
activation of an antitumor milieu.
Of note, high prevalence of CD80 positive cells was 
observed at the ENE invasive front. This protein is pre-
sent on dendritic cells, activated B cells and monocytes 
and its overexpression provides a costimulatory sig-
nal necessary for T cell activation and survival. A sig-
nificant overexpression of CD80 in colonic mucosa has 
been found in early stages of colorectal carcinogenesis 
and was demonstrated to play a role in immune surveil-
lance mechanisms in the transition from low-grade to 
high-grade dysplasia [32, 33]. However, a strong CD80 
expression has been associated to resistance to adju-
vant chemotherapy suggesting the failure of this specific 
immune surveillance mechanism in advanced stage of 
digestive tract cancer [34]. Thus, the association of ENE 
status with an overexpression of CD80 may be one of the 
factors which could potentially explain the more aggres-
sive biological behaviour displayed by metastatic CRCs 
with ENE [16]. The results of this exploratory study 
Fig. 2 a Mutational profiling of the 15 cases profiled through a hotspot multigene mutational custom panel, including 164 hotspot regions of 
AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53 genes. In red are the samples showing a different mutational landscape 
in comparison to the other matched samples. (scale bars = 100 µm). b Representative Sequenom MassArray output profiles for KRAS c.436G > A 
(p.A146T), PIK3CA c.1633G > A (p.A545K), BRAF c1799T > A (p.V600E) and NRAS c.35G > A (p.G12D) mutations. On the right the correspondent Sanger 
chromatogram
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call for further investigations about the immunological 
microenvironment of metastatic lymph nodes with ENE, 
also for addressing new potential therapeutic strategies.
Even on a relatively small series of cases and by analyz-
ing a limited panel of CRC-associated genes, our study 
lack to demonstrate any clonal ENE-associated nodal 
metastases specific molecular driver. Indeed, 73% of the 
cases show that the mutations which were found in the 
primary tumors are consistent with those observed in 
their matched lymph node metastases demonstrating 
that the tumor clones are still the same (observed for 
both ENE positive and ENE negative ones). Moreover, 
no difference was found between the ENE-associated 
nodal metastases and the ENE-negative one or the cor-
respondent primary tumor in the same patient. This lack 
of association may be explained with the small sample 
size of our study, but it is more likely that somatic muta-
tions are not a driver mechanism in the acquisition of 
the ENE phenotype in CRCs. Recent reports have dem-
onstrated an important clustering of cancer stem-like 
cells at the CRC invasive front and their important role 
in the development of tumor heterogeneity [35–38]. In 
the CRC setting, CD44 variant-positive cancer stem cells 
have been demonstrated to be resistant to redox stress in 
the tumor microenvironment by enhancing the ESRP1-
CD44v-xCT-GSH (cysteine/glutamate antiporter) axis 
[35, 38, 39], and thus these cells are almost unaffected 
by selective pressure determined by oxygen deprivation 
and anti-cancer treatments Another interaction involving 
beta-catenin in CRC regards CD200, a membrane pro-
tein that characterizes neoplastic cells with cancer stem 
properties [40]. Due to the important role of CD200 in 
regulating tumor microenvironment in this setting, its 
expression may be of importance also in ENE-positive 
CRCs. Future studies are therefore needed to better 
define the complete profiles of ENE-positive CRC cell 
clones.
With our study, we highlight that the biological mecha-
nisms on the basis of ENE in CRCs should be further 
investigated in the complex immunological microenvi-
ronment rather than in the genetic profiles of metastatic 
cells, including CD44 and CD200. It is also of importance 
that in other solid malignancies an ENE-specific molecu-
lar profile has been detected by comparing ENE-negative 
and ENE-positive cases [41], but in CRC the impor-
tance of metastases microenvironment may be more 
significant.
Conclusion
Overall our data demonstrated that there is, on one side, 
no specific molecular features based on our relatively lim-
ited genotypic study for the acquisition of the ENE phe-
notype but, on the other, the overexpression of CD80 and 
T lymphocytes/macrophages infiltration at the ENE inva-
sive front may suggest further investigations on a possible 
application of novel immunotherapeutic approaches in 
ENE-positive CRCs.
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